609Indexed trials
mesh condition
Attention Deficit Disorder with Hyperactivity
Intelligence
Attention Deficit Disorder with Hyperactivity intelligence: 609 indexed trials, 75 recruiting studies, 341 sponsors across 43 countries.
75Recruiting
341Sponsors
43Countries
Leading sponsors
Massachusetts General Hospital232 recruiting
Shire170 recruiting
Eli Lilly and Company110 recruiting
Children's Hospital Medical Center, Cincinnati110 recruiting
National Taiwan University Hospital110 recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.91 recruiting
Duke University91 recruiting
Supernus Pharmaceuticals, Inc.91 recruiting
Florida International University81 recruiting
Karolinska Institutet80 recruiting
National Institute of Mental Health (NIMH)81 recruiting
Hospital de Clinicas de Porto Alegre70 recruiting
Geographic activity
United States266trials
Israel35trials
France27trials
China26trials
Canada25trials
Taiwan23trials
United Kingdom18trials
Sweden14trials
Spain14trials
Germany13trials
Turkey (Türkiye)13trials
Brazil13trials
Leading interventions
Methylphenidate23trials
Atomoxetine14trials
Behavioral Parent Training6trials
Lisdexamfetamine6trials
atomoxetine5trials
methylphenidate5trials
Atomoxetine Hydrochloride5trials
Treatment as usual5trials
Methylphenidate Transdermal System4trials
Concerta4trials
Centanafadine4trials
400mg SPN-8123trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.